Vai al contenuto principale
xMedica

NCT07564414ClinicalTrials.gov

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for…

Fase 32500 partecipanti ricercati303 centri19 paesi

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-05-04; recorded start 2026-05-21
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 351 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 303 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,500 participants (target), run at 303 sites, across 19 countries.

How this score is built
  • Enrolment34/40

    2,500 participants (target)

  • Site count25/25

    303 sites

  • Country count15/15

    19 countries

  • Planned duration7/10

    Planned over about 23 months

  • Sponsor scale9/10

    Novo Nordisk A/S has led 320 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

Patologie

  • Obesity
  • Type 2 Diabetes

Idoneità

Idoneità
SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria : * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * BMI≥ 35.0 kg/m\^2. * Participants without T2D: No history of T2D and HbA1c \< 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c \< 10% (\< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised. Exclusion Criteria: * A self-reported change in body weight \> 5% within 90 days before screening, irrespective of medical records. * Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 3
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento2500 partecipanti ricercati

Sponsor e collaboratori

  • Novo Nordisk A/S Sponsor

Bracci e interventi

  • Cagrisema - dose level 1EXPERIMENTAL

    Participants will receive CagriSema at dose level 1 once weekly subcutaneously during the treatment period for 72 weeks.

  • Cagrisema - dose level 2ACTIVE_COMPARATOR

    Participants will receive CagriSema at dose level 2 once weekly subcutaneously during the treatment period for 72 weeks.

  • SemaglutideACTIVE_COMPARATOR

    Participants will receive Semaglutide once weekly subcutaneously during the treatment period for 72 weeks.

Interventi

  • Farmaco Cagrisema

    Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.

  • Farmaco Semaglutide

    Semaglutide will be administered subcutaneously.

Esiti misurati

  1. Esito primario

    Relative change in body weight

    Measured as percentage (%).

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  2. Esito secondario

    Relative change in body weight

    Measured as %.

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  3. Esito secondario

    Change in Body Mass Index (BMI)

    Measured as kilograms per square metre (kg/m\^2).

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  4. Esito secondario

    Number of participants who achieve greater than or equal to (≥) 30% weight reduction

    Measured as count of participants.

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  5. Esito secondario

    Number of participants who achieve ≥25% weight reduction

    Measured as count of participants.

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  6. Esito secondario

    Number of participants who achieve greater ≥ 20% weight reduction

    Measured as count of participants.

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  7. Esito secondario

    Change in waist circumference

    Measured in centimetre (cm).

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  8. Esito secondario

    Mean change in body weight

    Measured in kilograms (kg).

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  9. Esito secondario

    Number of participants who achieve a BMI less than (<) 30 kg/m^2

    Measured as count of participants.

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  10. Esito secondario

    Number of participants who achieve BMI <27 kg/m^2

    Measured as count of participants.

    Orizzonte temporale end of treatment (week 72)

  11. Esito secondario

    Number of participants who achieve normal BMI, defined as 18.5 lesser than or equal to (≤) BMI < 25 kg/m^2

    Measured as count of participants.

    Orizzonte temporale At end of treatment (week 72)

  12. Esito secondario

    Number of participants who achieve a waist-to-height ratio < 0.53

    Measured as count of participants.

    Orizzonte temporale At end of treatment (week 72)

  13. Esito secondario

    Ratio to baseline : Total cholesterol

    Measured in terms of ratio.

    Orizzonte temporale From baseline (week 0) to end of treatment (week 72)

  14. Esito secondario

    Ratio to baseline : High density lipoprotein (HDL) cholesterol

    Measured in terms of ratio.

    Orizzonte temporale From baseline (week 0) to end of treatment (week 72)

  15. Esito secondario

    Ratio to baseline : Low density lipoprotein (LDL) cholesterol

    Measured in terms of ratio.

    Orizzonte temporale From baseline (week 0) to end of treatment (week 72)

  16. Esito secondario

    Ratio to baseline : Very low density lipoprotein ( VLDL) cholesterol

    Measured in terms of ratio.

    Orizzonte temporale From baseline (week 0) to end of treatment (week 72)

  17. Esito secondario

    Ratio to baseline : Triglycerides

    Measured in terms of ratio.

    Orizzonte temporale From baseline (week 0) to end of treatment (week 72)

  18. Esito secondario

    Ratio to baseline: Free fatty acids

    Measured in terms of ratio.

    Orizzonte temporale From baseline (week 0) to end of treatment (week 72)

  19. Esito secondario

    Ratio to baseline : Non-HDL cholesterol

    Measured in terms of ratio.

    Orizzonte temporale From baseline (week 0) to end of treatment (week 72)

  20. Esito secondario

    Change in Short-Form-36 Health Survey Version 2.0 (SF-36v2) physical Function

    Measured as score on a scale. The SF-36v2 acute measures health-related quality of life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being.

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  21. Esito secondario

    Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) physical function

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning.

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  22. Esito secondario

    Change in glycated haemoglobin (HbA1c)

    Measured in %-points.

    Orizzonte temporale From randomisation (week 0) to end of treatment (week 72)

  23. Esito secondario

    Number of participants who achieve HbA1c <6.5%

    Measured as count of participants.

    Orizzonte temporale At end of treatment (week 72)

  24. Esito secondario

    Number of participants who achieve normal HbA1c <5.7%

    Measured as count of participants.

    Orizzonte temporale At end of treatment (week 72)

  25. Esito secondario

    Number of treatment-emergent adverse events (TEAEs)

    Measured in number of events.

    Orizzonte temporale From randomisation (week 0) to end of study (week 80)

  26. Esito secondario

    Number of treatment-emergent serious adverse events (TESAEs)

    Measured in number of events.

    Orizzonte temporale From randomisation (week 0) to end of study (week 80)

Date

Date
Data di inizio21 maggio 2026 (effettiva)
Conclusione primaria23 febbraio 2028 (stimata)
Conclusione19 aprile 2028 (stimata)
Prima pubblicazione4 maggio 2026 (effettiva)
Ultimo aggiornamento30 settembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltasettembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

1 centro sta reclutando

Argentina

Argentina
StrutturaCittàStato o regioneStato
OMI- Organización Médica de InvestigaciónBuenos AiresAttivo, non in reclutamento
Centro Medico Dra. Laura Maffei e Investigacion Clínica ApliBuenos AiresAttivo, non in reclutamento
Hospital Sirio LibanesBuenos AiresAttivo, non in reclutamento
Kynet RecoletaBuenos AiresAttivo, non in reclutamento
CEMEDICCABABuenos AiresAttivo, non in reclutamento
CEDIC Centro de Investigación ClínicaCABANon ancora in reclutamento
CIPREC ArenalesCABAAttivo, non in reclutamento
Centro Médico Viamonte SRLCABAAttivo, non in reclutamento
Centro de Investigaciones MetabólicasCapital FederalBuenos AiresAttivo, non in reclutamento
CICEMO- Consultorio (Av Directorio)Ciudad Autónoma de Buenos AiresBuenos AiresAttivo, non in reclutamento
Centro Médico ArsemaCiudad Autónoma de Buenos AiresBuenos AiresAttivo, non in reclutamento
Instituto CentenarioCiudad de Buenos AiresAttivo, non in reclutamento
Centro de Investigación C.I.C.E 9 de Julio - Sanatorio 9 de JulioSan Miguel de TucumánTucumán ProvinceAttivo, non in reclutamento
CEDIR - Centro de diagnóstico y rehabilitación Santa FeSanta FeAttivo, non in reclutamento
Sanatorio NorteSantiago del EsteroAttivo, non in reclutamento

Australia

Australia
StrutturaCittàStato o regioneStato
University of Sunshine Coast - Vitality VillageBirtinyaQueenslandAttivo, non in reclutamento
Emeritus Research MelbourneCamberwellVictoriaAttivo, non in reclutamento
Sydney Clinical TrialsCampbelltownNew South WalesAttivo, non in reclutamento
Gosford Renal ResearchGosfordNew South WalesAttivo, non in reclutamento
Sydney Cardiometabolic CentreLiverpoolNew South WalesAttivo, non in reclutamento
Hunter Diabetes CentreMerewetherNew South WalesAttivo, non in reclutamento
University of Sunshine Coast - South BrisbaneSouth BrisbaneQueenslandAttivo, non in reclutamento

Austria

Austria
StrutturaCittàStato o regioneStato
Medical University of GrazGrazAttivo, non in reclutamento
Ordination Winhofer-StöcklMattersburgAttivo, non in reclutamento
Fließer-Görzer [Ordination]Saint StefanAttivo, non in reclutamento
Universitätsklinikum AKH WienViennaAttivo, non in reclutamento
Klinik LandstraßeViennaAttivo, non in reclutamento
Ordination Dr. Günter SokolViennaAttivo, non in reclutamento
Klinik Hietzing 3. Med. Abt.ViennaAttivo, non in reclutamento
Itariu [Ordination]ViennaAttivo, non in reclutamento

Belgium

Belgium
StrutturaCittàStato o regioneStato
Anima Research CenterAlkenAttivo, non in reclutamento
Cliniques universitaires Saint-LucBrusselsNon ancora in reclutamento
KORMONTKluisbergenAttivo, non in reclutamento
CHU TivoliLa LouvièreAttivo, non in reclutamento
MECLINASMechelenAttivo, non in reclutamento
AZ Delta - RoeselareRoeselareAttivo, non in reclutamento
KORMONTZwalmAttivo, non in reclutamento

Bulgaria

Bulgaria
StrutturaCittàStato o regioneStato
MC For Life EOODBurgasAttivo, non in reclutamento
MC Kazanlak EOODKazanlakAttivo, non in reclutamento
Medical center Medi City 21 OODKyustendilAttivo, non in reclutamento
OCSOMCE - Dr. Albena Dinkova EOODPlevenAttivo, non in reclutamento
AIPSMCEMDID - Dr. Georgi Levterov EOODPlovdivCompletato
DCC Sveti Georgi EOODPlovdivAttivo, non in reclutamento
Hipocrat 9 - Dr. Rumyana Boykova - Draganova - AISPEMD EOODSofiaAttivo, non in reclutamento
DCC XX - Sofia EOOD, EndocrinologySofiaAttivo, non in reclutamento
MC Diamedical - 2013 OOD, SofiaSofiaAttivo, non in reclutamento
Medical Centre Medical Arts Medico-dental centreSofiaAttivo, non in reclutamento
DCC XXV Sofia EOOD, Endocrinology Consulting roomSofiaCompletato
UMHAT Prof. Dr. Stoyan Kirkovich ADStara ZagoraAttivo, non in reclutamento
AIPSMC Dr. Evelina Zlatanova EOODVarnaAttivo, non in reclutamento

Nella scheda del registro sono indicati altri 253 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

Non è stata registrata alcuna modifica da quando abbiamo acquisito questa scheda.

Viene registrata una modifica ogni volta che lo sponsor aggiorna la scheda del registro. Stato, date, arruolamento e centri compaiono qui man mano che cambiano.